Raising Capital in Life Sciences in 2022-2023: What Works?
By Greg Curhan
Raising money in the capital markets for a biopharma or life sciences company over the last few years has been quite a roller coaster ride. Funding among U.S. biotech startups reached a record high of $77 billion in 2021 (Crunchbase), as investors were attracted to expanding opportunities in genetics, therapeutics…Read More
Read More5 Lessons in Cash Management from a CFO
By Anne Samak de la Cerda
When I joined FLG in 2020, I brought 20+ years of experience as a finance executive and CFO to the firm. My current focus is technology businesses, including B2B Software and Consumer platforms as well as Healthcare and Life Sciences. I help teams drive strategies as they plan for growth,…Read More
Read MoreDebt Financing versus Equity Financing
By Eric Hall, Jonathan Wolter
[Editorial Note: This article was originally written by the late Eric Hall, FLG Partner and CFO. It was updated in January 2026 by Jonathan Wolter.] The Covid-19 pandemic of the past few years, spiking inflation, and supply chain disruptions have created an economic situation that is putting increasing pressure on…Read More
Read More“Speed to Exit”: How to Get an IPO Closed in Record Time
By Eric Hall
We’ve all heard the phrase “Speed to Market.” But how many have heard “Speed to Exit?” Maybe not many, since I just created it but it really is a phrase that should be part of every CFO’s vocabulary. Speed to exit is the driving force to get a liquidity event,…Read More
Read More